A novel serum extracellular vesicle protein signature to monitor glioblastoma tumor progression
International Journal of Cancer · 15.01.2023 · 152 (2) · 308-319
DOI: 10.1002/ijc.34261 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Cancer, online erschienen am 17.09.2022. Verfasst von Theophilos Tzaridis und 20 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Clinical Chemistry and Clinical Pharmacology, University Hospital, University of Bonn, Bonn, Germany. Hauptthemen laut MEDLINE: Glioblastoma, Extracellular Vesicles. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, NINDS NIH HHS, Deutsche Forschungsgemeinschaft.
Abstract (Originalsprache)
Detection of tumor progression in patients with glioblastoma remains a major challenge. Extracellular vesicles (EVs) are potential biomarkers and can be detected in the blood of patients with glioblastoma. In our study, we evaluated the potential of serum‐derived EVs from glioblastoma patients to serve as biomarker for tumor progression. EVs from serum of glioblastoma patients and healthy volunteers were separated by size exclusion chromatography and ultracentrifugation. EV markers were defined by using a proximity‐extension assay and bead‐based flow cytometry. Tumor progression was defined according to modified RANO criteria. EVs from the serum of glioblastoma patients (n = 67) showed an upregulation of CD29, CD44, CD81, CD146, C1QA and histone H3 as compared to serum EVs from healthy volunteers ( P value range:
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Clinical Chemistry and Clinical Pharmacology, University Hospital, University of Bonn, Bonn, Germany.
- Division of Clinical Neurooncology, Department of Neurology, Center of Integrated Oncology Aachen-Bonn-Cologne-Düsseldorf, Partner Site Bonn, University of Bonn, Bonn, Germany.
- Tumor Initiation & Maintenance Program, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California, USA.
- Department I of Internal Medicine, Center for Integrated Oncology Aachen-Bonn-Cologne-Düsseldorf, Partner Site Cologne, Center for Molecular Medicine Cologne, University of Cologne, Cologne, Germany.
- Institute for Medical Biometry, Informatics and Epidemiology, Institute for Genomic Statistics and Bioinformatics, Medical Faculty, University of Bonn, Bonn, Germany.
- Department of Neurology and Wilhelm Sander NeuroOncology Unit, University Hospital Regensburg, Regensburg, Germany.
ORCID-Profile: Theophilos Tzaridis, Daniel Bachurski, Farhad Shakeri, Lothar Haeberle, Katrin S Reiners
Förderung
- NCI NIH HHS
- NINDS NIH HHS
- Deutsche Forschungsgemeinschaft
Zitieren
APA
Tzaridis, T., Weller, J., Bachurski, D., Shakeri, F., Schaub, C., Hau, P., Buness, A., Schlegel, U., Steinbach, J. P., Seidel, C., Goldbrunner, R., Schäfer, N., Wechsler-Reya, R. J., Hallek, M., Scheffler, B., Glas, M., Haeberle, L., Herrlinger, U., Coch, C., …, & Hartmann, G. (2023). A novel serum extracellular vesicle protein signature to monitor glioblastoma tumor progression. International Journal of Cancer, 152(2), 308-319. https://doi.org/10.1002/ijc.34261
Vancouver
Tzaridis T, Weller J, Bachurski D, Shakeri F, Schaub C, Hau P, et al. A novel serum extracellular vesicle protein signature to monitor glioblastoma tumor progression. International Journal of Cancer. 2023;152(2):308-319. doi:10.1002/ijc.34261
BibTeX
@article{Tzaridis2023,
author = {Tzaridis, Theophilos and Weller, Johannes and Bachurski, Daniel and Shakeri, Farhad and Schaub, Christina and Hau, Peter and Buness, Andreas and Schlegel, Uwe and Steinbach, Joachim-Peter and Seidel, Clemens and Goldbrunner, Roland and Schäfer, Niklas and Wechsler-Reya, Robert J and Hallek, Michael and Scheffler, Björn and Glas, Martin and Haeberle, Lothar and Herrlinger, Ulrich and Coch, Christoph and Reiners, Katrin S and Hartmann, Gunther},
title = {A novel serum extracellular vesicle protein signature to monitor glioblastoma tumor progression},
journal = {International Journal of Cancer},
year = {2023},
volume = {152},
number = {2},
pages = {308--319},
doi = {10.1002/ijc.34261}
}
EUVIMED